Key Benefits:
The President of the Republic,
On the report of the Prime Minister and the Minister for Foreign Affairs,
Having regard to Articles 52 to 55 of the Constitution;
Given the Decree No. 53-192 of 14 March 1953, as amended concerning the ratification and publication of international commitments entered into by France;
Having regard to Decree No. 91-274 of 13 March 1991 on the publication of the Anti-Doping Convention (set out in an annex), Signed in Strasbourg on 16 November 1989,
Describes:
The amendment to the Annex to the Anti-Doping Convention, adopted by the Monitoring Group at its 24th meeting 14 and 15 November 2006 in Strasbourg, will be published in the Official Journal of the French Republic.
The Prime Minister and the Minister for Foreign Affairs shall be responsible for the execution of this Decree, each of which shall be published in the Official Journal of the French Republic.
A M E N D E M E N T
TO THE SCHEDULE TO THE CONVENTION AGAINST DOPING, ADOPTED BY THE FOLLOWING GROUP AT ITS 24th MEETING NOVEMBER 14 AND 15, 2006 TO STRASBOURG, ENTRY EN EFFECTIVE JANUARY 1, 2007
Use of any medication should be limited to medically justified indications.
PROHIBITED SUBSTANCES AND METHODS
PERMANENT
(in and out of competition)
Substances Prohibited
S1. Anabolic Agents
Anabolic agents are prohibited.
1. Anabolic androgenic Steroids (SAA):
a) Exogenous SAA *, including:
1-androstenediol (5a-androst-1-ene-3b, 17b-diol); 1-androstenedione (5a-androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17a-ethynyl-17b-hydroxyandrost-4-eno [2,3-d] isoxazole); dehydrochlormethyltestosterone (4-chloro-17b-hydroxy-17a-methylandrosta-1,4-dien-3-one); deoxymethyltestosterone (17a-methyl-5a-androst-2-en-17b-ol); drostanolone; ethylestrenol (19-nor-17a-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17b-hydroxy-17a-methyl-5a-androstano [2,3-c] - furazan); gestrinone; 4-hydroxytestosterone (4,17b-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17b-hydroxy-17a-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2a, 17a-dimethyl-5a-androstane-3-one-17b-ol); methyldienolone (17b-hydroxy-17a-methylestra-4,9-dien-3-one); methyl-1-testosterone (17b-hydroxy-17a-methyl-5a-androst-1-en-3-one); methylnortestosterone (17b-hydroxy-17a-methylestr-4-en-3-one); methyltrienolone (17b-hydroxy-17a-methylestra-4,9,11-trien-3-one); Methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c] pyrazole-5a-etioallocholane-17b-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17b-hydroxy-5a-androst-l-ene-3-one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-triene-17b-ol-3-one); trenbolone and other substances Having a similar chemical structure or a similar biological effect (s).
b) Endogenous SAA * *:
Androstenediol (androst-5-ene-3b, 17b-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17b-hydroxy-5a-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites or isomers:
5a-androstane-3a, 17a-diol; 5a-androstane-3a, 17b-diol; 5a-androstane-3b, 17a-diol; 5a-androstane-3b, 17b-diol; Androst-4-ene-3a, 17a-diol; androst-4-ene-3a, 17b-diol; androst-4-ene-3b, 17a-diol; androst-5-ene-3a, 17a-diol; androst-5-ene-3a, 17b-diol; androst-5-ene-3b, 17a-diol; 4-androstenediol (androst-4-ene-3b, 17b-diol); 5-androstenedione (androst-5-ene-3,17-dione); ep-dihydrotestosterone; 3a-hydroxy-5a-androstan-17-one; 3b-hydroxy-5a-androstan-17-one; 19-norandrosterone; 19-noretiocholanolone.
In the case of androgenic anabolic steroid that can be produced in a manner Endogenous, a sample will be considered to contain this Prohibited Substance if the concentration of the Prohibited Substance or its Metabolites or Markers and/or any other relevant report in the Athlete's Sample differs Sufficient normal values found in humans for normal endogenous production to be unlikely. In such cases, a sample will not be considered to contain a Prohibited Substance if the Athlete proves that the concentration of Prohibited Substance or its Metabolites or Markers and/or any other relevant report in the Sample The Athlete is attributable to a physiological or pathological condition.
In all cases, and regardless of the concentration, the Athlete's sample will be considered to contain a Prohibited Substance and the Laboratory will report a result An abnormal analysis if, based on a reliable method of analysis (e.g. SMRI), the laboratory can demonstrate that the prohibited substance is of exogenous origin. In this case, no further investigation will be required.
When the reported value is at levels normally found in humans and the reliable method of analysis (e.g. SMRI) did not determine the exogenous origin of the substance, but there are serious indications, such as comparison with endogenous steroidal reference profiles, of a possible use of a prohibited substance, the anti-doping organization Will conduct a more thorough investigation, which will include a review of all previous and/or subsequent controls, to determine whether the result is attributable to a physiological or pathological condition, or as a result of the catch A prohibited substance of exogenous origin.
When a laboratory has reported a T/E ratio greater than four (4) for one (1) and the application of a reliable analytical method (e.g. SMRI) has not demonstrated that the prohibited substance was of exogenous origin, a complementary investigation may be conducted, including a review of all previous and/or subsequent controls, to determine if the result is attributable to a Physiological or pathological condition, or results from the taking of a prohibited substance of exogenous origin. If a laboratory reports an adverse analytical result based on the application of a reliable analytical method (e.g. SMRI), demonstrating that the prohibited substance is of exogenous origin, no further investigation will be required and the athlete's sample will be considered to contain a prohibited substance.
When a reliable method of analysis (e.g. SMRI) has not been applied and a minimum of three results of prior checks are not available, the responsible anti-doping organization shall establish a longitudinal profile of the Athlete by performing at least three unannounced tests during a Three-month period. If the longitudinal profile of the athlete subject to these complementary controls is not physiologically normal, the laboratory will result in an abnormal analysis.
In extremely rare individual cases, the boldenone can be found Endogenously and at very low levels of a few nanograms per millilitre (ng/mL) in the urine. When such a very low level of boldenone is reported by the laboratory and the application of a reliable method of analysis (e.g. SMRI) does not demonstrate that the substance is of exogenous origin, a complementary investigation may be conducted, including a review of all previous and/or subsequent controls. When a reliable method of analysis (e.g. SMRI) has not been applied, the responsible anti-doping organization shall establish a longitudinal profile of the Athlete by conducting at least three random tests for a period of three months. If the longitudinal profile of the athlete subject to these complementary controls is not physiologically normal, the laboratory will make an adverse analytical result.
For 19-norandrosterone, an Adverse Analytical Finding by the Laboratory Is considered to be scientific and valid evidence demonstrating the exogenous origin of the prohibited substance. In this case, no further investigation is required.
If the athlete refuses to cooperate with the additional tests, the sample will be considered to contain a prohibited substance.
2. Other anabolic agents, including but not limited to: clenbuterol, tibolone, zeranol, zillegol.
S2. Hormones and Related Substances
The following substances, including other substances with a similar chemical structure or similar biological effect (s), and their release factors, are Prohibited:
1. Erythropoietin (EPO).
2. Growth Hormone (hGH), growth factors analogous to insulin (e.g. IGF-1), mechanical growth factors (MGFs).
3. Gonadotrophins (LH, hCG), prohibited in male athletes only.
4. Insulin.
5. Corticotrophins.
Unless the athlete can demonstrate that the concentration was due to a physiological or pathological condition, a sample will be considered to contain a prohibited substance (as listed above) when the Concentration of prohibited substance or its metabolites or markers and/or any other relevant report in the athlete's sample is above normal human values and normal endogenous production is unlikely.
If The laboratory can demonstrate, based on a reliable method of analysis, that the prohibited substance is of exogenous origin, the athlete's sample will be considered to contain a prohibited substance and will be reported as an analysis result In
, the presence of substances having a similar chemical structure or a similar biological effect (s), diagnostic marker (s) or hormone release factors listed above, Or any other result indicating that the detected substance is of exogenous origin, will be considered to indicate the use of a Prohibited Substance and will be reported as an Adverse Analytical Finding.
S3. Beta-2 agonists
All beta-2 agonists, including their D-and L-isomers, are prohibited.
As an exception, formoterol, salbutamol, salmeterol and terbutaline, when used by inhalation, require An Abbreviated Therapeutic Use Exemption.
Whichever form of the therapeutic use authorization is granted, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered As an Adverse Analytical Finding, unless the Athlete demonstrates that this abnormal result is consistent with the therapeutic use of inhaled salbutamol.
S4. Agents with anti-estrogen activity
The following classes of anti-estrogenic substances are prohibited:
1. Aromatase inhibitors, including but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone.
2. Selective estrogen receptor modulators, including but not limited to: raloxifene, tamoxifen, torecfen.
3. Other anti-estrogenic substances, including but not limited to: clomifen, cyclofenil, fulvestrant.
S5. Diuretics and Other Masking Agents
Masking agents are prohibited. They include:
Diuretics *, epitestosterone, probenaecid, alpha-reductase inhibitors (e.g. Dutasteride and finasteride), plasma substitutes (e.g. Albumin, dextran, hydroxyethylamidon) and other substances having a similar biological effect (s).
Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, ecrynic acid, furosemide, Indapamide, mestolazone, spironolactone, thiazides (e.g. Bendroflumethazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances having a similar chemical structure or a similar biological effect (s) (except drosperinone, which is not prohibited).
Prohibited Methods
M1. Oxygen Transfer Improvements
The following is prohibited:
1. Blood doping, including the use of autologous, homologous or heterologous blood products, or red blood cells of any origin.
2. Artificial improvement in the consumption, transport or release of oxygen, including but not limited to perfluorinated chemicals, faproxiral (RSR13) and modified hemoglobin products (e.g. Haemoglobin-based blood substitutes, cross-linked hemoglobin products).
M2. Chemical and physical manipulation
1. Falsification, or attempted forgery, in order to alter the integrity and validity of samples collected during doping controls is prohibited. This category includes, but is not limited to, catheterization, substitution and/or alteration of urine.
2. Intravenous infusions are prohibited except in the legitimate framework of medical treatment.
M3. Gene Doping
The non-therapeutic use of cells, genes, genetic elements, or modulation of gene expression, with the ability to increase athletic performance, is prohibited.
PROHIBITED
SUBSTANCES AND METHODS
In addition to categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:
Substances Prohibited
S6. Stimulants
All stimulants (including their optical isomers [D- and L -] when applicable) are prohibited, except imidazole derivatives for topical application and stimulants in the Program 2007 *.
The stimulants include:
Adrafinil, adrenaline * *, amfepramone, amiphenazole, amphetamine, amphetamines, benzphetamine, benzylpiperazine, bromantan, cathine * **, clobenzorex, cocaine, cropropamide, crotamide, Cyclazodone, dimethylamphetamine, ephedrine * **, timivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamine, fencamine, fenestylline, fenfluramine, fenproporex, furfenorex, heptaminol, isomethepene, levmethamfketamine, meclofenoxate, Mefenorex, mephentermine, mesocarb, methamphetamine (D -), methylenedioxyamphetamine, methylenedioxymethamphetamine, p-methylamphetamine, methylephedrine * ***, methylphenidate, modafinil, nicethamide, norfenefrine, norfenfluramine, octopamine, ortstain, Oxilofrin, parahydroxyamphetamine, pemoline, pentetrazole, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4-phenylpiracem (carphedon); prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane, and others Substances with a similar chemical structure or similar biological effect (s).
A stimulant being Not expressly mentioned as an example in this section should be considered a specific Substance only if the Athlete can establish that the substance is particularly likely to result in an unintentional violation of the Anti-doping regulations because of its frequent presence in drugs, or if it is less likely to be used successfully as a doping agent.
S7. Narcotics
The following narcotics are prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.
S8. Cannabinoids
Cannabinoids (e.g. Hashish, marijuana) is prohibited.
S9. Glucocorticoids
All glucocorticoids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires an authorization to use for therapeutic purposes.
Other routes of administration (intra-articular injection/periarticary/ peritendous/peridural/ intradermal and by inhalation) require authorization Abbreviated therapeutic use, with the exception of the following routes of administration.
Topical preparations used to treat dermatological diseases (including iontophoresis/phonhoresis), atrial, nasal, Ophthalmologic, buccal, gingival and peri-anal are not prohibited and therefore do not require any therapeutic use.
PROHIBITED SUBSTANCES IN CERTAIN SPORTS
P1. Alcohol
Alcohol (ethanol) is prohibited in competition only, in the following sports.
Detection will be done by ethylometry and/or blood analysis. The violation threshold (hematological values) is indicated in parentheses:
Aeronautical (FAI) (0.20 g/L);
Automobile (FIA) (0.10 g/L);
Boules (CMSB), (0.10 g/L) (BCS);
Karate (WKF) (0.10 g/L);
Motorcycling (FIM) (0.10 g/L);
Motonautic (UIM) (0.30 g/L);
Modern Pentathlon (UIPM) (0.10 g/L) for shooting events;
Archery (FITA, IPC) (0.10 g/L).
P2. Beta-blockers
Unless otherwise indicated, beta-blockers are prohibited in competition only, in the following sports:
Aeronautical (FAI);
Automobile (FIA);
Billard (WCBS);
Bobsleigh (FIBT) ;
Boules (CMSB, IPC balls);
Bridge (FMB);
Curling (WCF);
Gymnastics (FIG);
Wrestling (FILA);
Motorcycling (FIM);
Modern Pentathlon (UIPM) for shooting events;
Quilles (FIQ);
Ski (FIS) For ski jumping, freestyle jump/halfpipe and snowboard halfpipe/big air;
Tir (ISSF, IPC) (also prohibited out of competition);
Archery (FITA, IPC) (also prohibited out of competition);
Sailing (ISAF) for the players in the game Only:
Acebutolol, alprenolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, cartesolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, Oxprenolol, pindolol, propranolol, sotalol, timolol.
SPECIFIC SUBSTANCES
" Specific substances " * are listed below:
All beta-2 agonists by inhalation, except Salbutamol (free plus glucuronide) for a concentration greater than 1000 ng/mL and clenbuterol;
Probaecide;
Cathine, cropropamide, crotamide, ephedrine, tamivan, famprofazone, heptaminol, isomethepene, levmethamphetamine, Meclofenoxate, p-methylamphetamine, methylephedrine, nicethamide, norfenefrin, octopamine, ortstamine, oxilofrin, phenpromethamine, propylhexedrine, selegiline, sibutramine, tuaminoheptane, and any other stimulant not specifically mentioned in the Section S6 for which the athlete demonstrates that he meets the conditions described in section S6;
Cannabinoids;
All glucocorticoids;
Alcohol;
All beta-blockers.
Done at Paris, 11 January 2007.
Jacques Chirac
By the President of the Republic:
The Prime Minister,
Dominique de Villepin
The Minister for Foreign Affairs,
Philippe Douste-Blazy
